Physician profile
Nenad Antic
NPI 1346293883
$20,098.61
in general payments reported to CMS, 2019-2025
76 companies · $2,424 in 2025
The $2,424 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,669 · 2020: $629 · 2021: $3,919 · 2022: $2,891 · 2023: $4,841 · 2024: $3,724 · 2025: $2,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,507.97 |
| Education | $481.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,479.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,322.64 | 2019-2025 | Enhertu, Tagrisso, Imfinzi |
| Janssen Biotech, INC. | $1,223.98 | 2019-2025 | Darzalex, Imbruvica, Rybrevant |
| Pfizer INC. | $1,210.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,141.00 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,132.42 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $799.25 | 2020-2025 | Fruzaqla, Ninlaro, Advate |
| Celgene Corporation | $682.61 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Eisai INC. | $644.29 | 2021-2025 | |
| Incyte Corporation | $611.41 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $596.87 | 2020-2025 | Enhertu, Vanflyta |
| Astellas Pharma US INC | $592.12 | 2019-2025 | Xospata, Xtandi, Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $543.18 | 2019-2023 | Imbruvica, Epkinly |
| Glaxosmithkline, LLC. | $512.47 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Gilead Sciences, INC. | $446.18 | 2022-2025 | Trodelvy |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $444.15 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Amgen INC. | $432.32 | 2020-2023 | Lumakras, Nplate, Xgeva |
| Lilly USA, LLC | $398.22 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Alexion Pharmaceuticals, INC. | $379.86 | 2021-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $355.65 | 2019-2025 | |
| Genzyme Corporation | $324.12 | 2020-2024 | |
| Puma Biotechnology, INC. | $296.43 | 2019-2025 | |
| Genentech USA, INC. | $262.54 | 2019-2025 | Phesgo, Venclexta, Itovebi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.37 | 2020-2025 | Gilotrif |
| Abbvie INC. | $239.84 | 2023-2025 | Venclexta |
| Rigel Pharmaceuticals, INC. | $212.87 | 2019-2024 | Rezlidhia, Tavalisse |
| Kite Pharma, INC. | $202.69 | 2021-2023 | Yescarta |
| Array Biopharma INC | $186.75 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Blueprint Medicines Corporation | $168.80 | 2021-2025 | Ayvakit |
| Karyopharm Therapeutics INC. | $165.24 | 2021-2025 | Xpovio |
| Taiho Oncology, INC. | $154.04 | 2019-2024 | |
| Pharmaessentia USA Corporation | $144.34 | 2022-2025 | Besremi |
| Exelixis INC. | $142.05 | 2021-2024 | Cabometyx |
| Emd Serono, INC. | $122.88 | 2021-2024 | Bavencio |
| Stemline Therapeutics INC. | $120.47 | 2023-2025 | Orserdu, Elzonris |
| Global Blood Therapeutics, INC. | $111.00 | 2020-2021 | |
| Adc Therapeutics America, INC. | $108.71 | 2023-2024 | |
| Morphosys, US INC. | $107.41 | 2021-2023 | Monjuvi |
| Sobi, INC | $104.29 | 2022-2025 | |
| Agios Pharmaceuticals, INC. | $101.89 | 2023-2025 | Pyrukynd |
| Genmab U.S., INC. | $101.84 | 2024-2025 | Epkinly |
| Tersera Therapeutics LLC | $101.51 | 2022-2025 | Xermelo, Zoladex |
| Jazz Pharmaceuticals INC. | $100.75 | 2021-2022 | |
| Mirati Therapeutics, INC. | $96.64 | 2023-2024 | Krazati |
| Dova Pharmaceuticals | $94.52 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $76.79 | 2023-2025 | Orgovyx |
| Boston Scientific Corporation | $73.65 | 2023-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Bodyguardian |
| Emmaus Medical, INC. | $70.83 | 2020-2022 | |
| Eusa Pharma (US) LLC | $67.56 | 2021 | |
| Dendreon Pharmaceuticals LLC | $67.37 | 2021-2025 | Provenge |
| Beone Medicines USA, INC. | $60.20 | 2025 | Brukinsa |
| Alnylam Pharmaceuticals INC. | $55.45 | 2021-2025 | Givlaari |
| Aveo Pharmaceuticals, INC. | $55.10 | 2024 | |
| Recordati_rare_diseases_inc. | $54.27 | 2025 | Enjaymo, Sylvant |
| Myriad Genetic Laboratories, INC. | $40.22 | 2021 | |
| Tolmar, INC. | $39.36 | 2023-2024 | |
| Ge Healthcare | $38.72 | 2022 | |
| Servier Pharmaceuticals LLC | $36.25 | 2025 | |
| Immunocore Limited | $34.05 | 2024 | Kimmtrak |
| Ipsen Biopharmaceuticals, INC | $33.15 | 2023-2024 | Somatuline Depot, Onivyde |
| Beigene USA, INC. | $32.50 | 2024 | Brukinsa |
| Geron Corporation | $29.91 | 2025 | Rytelo |
| Tempus Ai, INC | $28.54 | 2024 | |
| Legend Biotech USA INC. | $23.25 | 2025 | Carvykti |
| Acrotech Biopharma INC. | $22.47 | 2021 | |
| Epizyme, INC. | $21.94 | 2022 | |
| Novo Nordisk INC | $21.36 | 2021 | |
| Verastem, INC. | $20.81 | 2019 | |
| Sirtex Medical INC | $18.75 | 2024 | Sir-Spheres Microspheres |
| Mylan Institutional INC. | $16.99 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.32 | 2025 | Danziten, Vivimusta |
| Deciphera Pharmaceuticals INC. | $16.29 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $14.95 | 2022 | |
| Foundation Medicine, INC. | $14.64 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.20 | 2023 | Sancuso |
| Iovance Biotherapeutics, INC. | $6.48 | 2025 | Amtagvi |
Drugs and devices associated with these payments
Enhertu $869Keytruda $585Lenvima $465Imbruvica $360Ultomiris $313Darzalex $290Scemblix $279Kisqali $262Trodelvy $258Tukysa $255Verzenio $242Ibrance $225Opdivo $222Reblozyl $203Jaypirca $201Lynparza $195Epkinly $190Braftovi $187Tagrisso $182Monjuvi $175Orgovyx $172Zejula $168Jemperli $163Stivarga $163Rybrevant $160Erleada $156Adcetris $148Venclexta $138Mektovi $137Xtandi $136Fruzaqla $132Ninlaro $131Besremi $128Bosulif $117Tecvayli $116Imfinzi $114Jakafi $109Welireg $104Piqray $104Elrexfio $101Orserdu $100Krazati $96.64Xospata $93.83Brukinsa $92.70Mekinist $89.69Lonsurf $87.83Inqovi $87.83Doptelet $84.09Tivdak $83.56Nubeqa $83.18Pyrukynd $82.26Pomalyst $81.73Fabhalta $79.39Sarclisa $71.20Retevmo $66.52Talvey $65.98Bavencio $65.83Talzenna $65.69Ayvakit $64.88Xpovio $60.99Pemazyre $58.81Opdualag $57.48Rezlidhia $56.63Tavalisse $56.63Phesgo $55.97Fotivda $55.10Enjaymo $54.45Advate $51.47Vitrakvi $51.09Yescarta $50.54Calquence $50.28Lorbrena $49.41Zynyz $48.02Carvykti $46.75Promacta $45.50Therasphere Y90 Glass Microspheres 10 Gbq $45.22Besponsa $42.64Inlyta $41.14Eligard $39.36Lumakras $38.78Gilotrif $38.66Paxlovid $36.89Tibsovo $36.25Xermelo $35.71Alunbrig $34.41Kimmtrak $34.05Provenge $33.98Padcev $33.77Onivyde $33.15Somatuline Depot $33.15Zoladex $32.74Iclusig $32.54Lupron Depot $31.07Ojjaara $30.19Rytelo $29.91Xofigo $29.81Vanflyta $28.80Bodyguardian $28.43Keytruda Qlex $28.33Givlaari $27.71
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nenad Antic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.